Knee meniscus. Cystic meniscus, unspecified medial meniscus, unspecified knee
Conditions
Interventions
Intervention 1: Intervention group: Fifteen patients with knee meniscus receive platelet lysate (PL) as the intervention group. Initially, receive informed consent from the patients and the following
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Men and women between the ages of 18 and 75 with OA diagnosis based on the American College of Rheumatology Analog scale of knee pain (VAS) equal to or greater than 2.5 People with at least 6 months of history of meniscus in both knees Radiological classification scale Kellgren-Lawrence 1 or 2 The availability of individual during the study period BMI Between 20 and 35 Positive joint line tenderness test Positive thessaly test
Exclusion criteria
Exclusion criteria: Pregnant women or women who are breastfeeding People with malignancy,People with severe heart disease, uncontrolled diabetes mellitus, rheumatoid arthritis, hemorrhagic diseases, history of anemia, arthritis, fibromyalgia and chronic fatigue syndrome Those linked to acetaminophen or Vicodin or a history of drug misuse History of cortisone injections in the last 6 weeks The use of non-steroidal anti-inflammatory drugs 1 week ago Having hemoglobin less than 11 g / dl and platelet count less than 150000 / mµ The use of inhibitors of platelet aggregation and anti-coagulation such as heparin History of knee surgery in the last 3 months Extraordinary deformation (varus >5?, valgus >5?)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determining knee pain by VAS in all phases of clinical trial. Timepoint: 1, 3, 6 and 12 months after the first injection. Method of measurement: Questionnaire (VAS).;Determination of knee function by WOMAC and KOOS in all phases of clinical trial. Timepoint: 1, 3, 6 and 12 months after the first injection. Method of measurement: Questionnaire (WOMAC), Questionnaire (KOOS).;Determine the range of knee motion by manual joiniometry in all phases of clinical trial. Timepoint: 1, 3, 6 and 12 months after the first injection. Method of measurement: Range of motion (Degree). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehdi Yousefi
Tabriz University of Medical Sciences
Outcome results
None listed